Grunenthal (PRIVATE.GRUNENTHAL)

Overall impact
B (72)

Commentary

Grunenthal is a strong overall performer. With a 'B' rating of 72.4 for overall impact (85th percentile compared to all companies), Grunenthal ranks 68th out of 242 industry peers, behind Synthon, Assembly Biosciences, Piramal Enterprises and 64 others, and ahead of Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 171 others. On top material causes for Grunenthal's industry (Pharmaceuticals), Grunenthal performs well in Accountable Institutions (95.1 score), Disaster Readiness and Effective Aid (94.8), Decent, Safe Work Opportunities (85.7) and 27 other causes where it received an 'A' score and performs poorly in Reduced Use of tobacco (39.6 score), Disease Eradication (26.3), Disease Eradication (26.3) and 3 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.GRUNENTHAL
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1946
Employees
4,400
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Germany
Share classes
PRIVATE.GRUNENTHAL
Description
Operator of a pharmaceutical company intended to serve clients across Germany. The company invests in research and development to treat unmet medical needs and bring products to markets that aid in pain treatment and management, thereby enabling clients with effective and life-changing medicines.
Material causes
Ethos considers the following causes material for Grunenthal, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.